Pulse Biosciences Inc. (PLSE)
| Bid | 19.85 |
| Market Cap | 1.24B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.83 |
| PE Ratio (ttm) | -24.19 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 20.25 |
| Volume | 101,387 |
| Avg. Volume (20D) | 161,945 |
| Open | 20.07 |
| Previous Close | 20.27 |
| Day's Range | 19.66 - 20.28 |
| 52-Week Range | 6.59 - 25.00 |
| Beta | undefined |
About PLSE
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed i...
20 hours ago · businesswire.com
Pulse Biosciences To Present at the TD Cowen 45th Annual Health Care ConferenceMIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) , a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced plans...
2 months ago · businesswire.com
Pulse Biosciences, Inc. Announces Election to Exercise Company WarrantsHAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano...